TIDMOXB

Oxford Biomedica PLC

20 March 2015

Oxford BioMedica to Present at 3(rd) Annual Regen Med Investor Day

London, UK - 20 March 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE:OXB), a leading gene and cell therapy company, announces that Dr Paul Blake, Chief Development Officer, will present at the 3(rd) Annual Regen Med Investor Day, being held Wednesday, March 25, 2015 in New York City.

Dr. Blake will present at 2:40pm ET / 6.40pm GMT to attending investors. During his presentation Dr. Blake will discuss Oxford BioMedica's expertise in the clinical development and manufacturing of gene and cell therapies.

Details of the Oxford BioMedica presentation are as follows:

   Event:                   ARM's Regen Med Investor Day 
   Date:                    March 25, 2015 
   Time:                    2.40pm ET / 6.40pm GMT 
   Location:             Metropolitan Club, One East 60th Street, New York, NY 10022

At the time of the ARM Regen Med Investor Day, a live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcast and will be published on the event's website shortly after the conference as well as on the company's website in the media section: http://www.oxfordbiomedica.co.uk/webcasts-and-audio/.

- Ends -

 
 For further information, please 
  contact: 
  Oxford BioMedica plc:                    Tel: +44 (0)1865 
   John Dawson, Chief Executive Officer     783 000 
   Tim Watts, Chief Financial Officer 
  Consilium Strategic Communications       Tel: +44 (0)20 
   Mary-Jane Elliott/Matthew Neal/Chris     3709 5700 
   Welsh/Laura Thornton

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector(R) IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Company has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk .

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGGUUCWUPAGMB

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Oxford Biomedica Charts.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Oxford Biomedica Charts.